EMFAT
CHRS icon

Emerald Mutual Fund Advisers Trust’s Coherus Oncology CHRS Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-191,245
Closed -$1.84M – 222
2022
Q3 		$1.84M Buy
+191,245
New +$1.94M 0.12% 134

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's CHRS Position: Q4 2022 in Review

Emerald Mutual Fund Advisers Trust sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 191,245 shares — an estimated $1.84M sold.

Emerald Mutual Fund Advisers Trust first reported a position in CHRS in Q3 2022 and held it in 1 quarter. The position peaked at $1.84M in Q3 2022. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Emerald Mutual Fund Advisers Trust reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 191,245 Coherus Oncology shares in Q4 2022, an estimated $1.84M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Coherus Oncology in Q3 2022 and held it in 1 quarter.
  • Emerald Mutual Fund Advisers Trust's Coherus Oncology position peaked at $1.84M in Q3 2022.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2022, filed 3 Feb 2023.